The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 22, 2007

Filed:

Aug. 13, 1999
Applicants:

Gregg A. Hastings, Westlake Village, CA (US);

Zdenka L. Jonak, Devon, PA (US);

Stephen H. Trulli, Havertown, PA (US);

James A. Fornwald, Norristown, PA (US);

Jonathan A. Terrett, Oxon, GB;

Inventors:

Gregg A. Hastings, Westlake Village, CA (US);

Zdenka L. Jonak, Devon, PA (US);

Stephen H. Trulli, Havertown, PA (US);

James A. Fornwald, Norristown, PA (US);

Jonathan A. Terrett, Oxon, GB;

Assignees:

Human Genome Sciences, Inc., Rockville, MD (US);

Beth Israel-Deaconess Medical Center, Boston, MA (US);

SmithKline Beecham Corporation, King of Prussia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/00 (2006.01); C12N 15/12 (2006.01); C12N 15/63 (2006.01); C07N 21/04 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.


Find Patent Forward Citations

Loading…